Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.

ABSTRACT:

Background

Safety data on disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) during breastfeeding are limited.

Objective

Assess safety outcomes for offspring breastfed by mothers undergoing glatiramer acetate (GA; Copaxone^®) treatment.

Methods

This non-interventional, retrospective study used German Multiple Sclerosis and Pregnancy Registry data. Participants had RMS, a live birth, and received GA or no DMT during breastfeeding.

Results

GA cohort: 58 mothers/60 offspring; matched controls: 60 mothers/60 offspring; 86.7% (GA) and 25% (control) of offspring were born to mothers who had GA at some point during pregnancy. Maternal demographics and disease activity were comparable. Annualized number of hospitalizations was similar f

SUBMITTER: Ciplea AI 

PROVIDER: S-EPMC9315183 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature